Clinical Research Directory

Inclusion Criteria: * Male or female, aged 40 to 75 at the time of signing informed consent. * Diagnosed with COPD according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD). * The ratio of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)FEV1/FVC is \< 70% after inhalation of bronchodilators. * The diffusion function of carbon monoxide (DLCO) is ≥ 20% and \< 80% of the predicted value at screening. * Tolerated to pulmonary function tests. * Tolerated to bronchoscopy * Voluntary to sign the informed consent, coordinated to finish the trial-related procedures and tests, and capable of recording or stating the change of disease condition in a relatively complete manner. Exclusion Criteria: * Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant); * Subjects with a positive result for any of the following tests at screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. But except the followings: 1. Hepatitis B virus carriers (only HBsAg positive without any hepatitis symptom or sign, and all liver function tests present normal results or abnormal markers without clinical significance by the assessment of investigators); 2. Cured hepatitis C patients (negative in HCV ribonucleic acid (RNA) test); * Subject with assessed survival time of \< 1 year by investigators at screening; * Subject with malignant tumors or a history of malignant tumors at screening; * Subject with infections in lung or other sites, requiring intravenous drug treatment within a week prior to screening; * Subject with more than 4 moderate-to-severe AECOPD, resulting in hospitalization within a year prior to screening; * Subject with one or more pathogenetic or serologic findings of the novel coronavirus infection, or symptoms of suspected infection within 6 weeks prior to screening; * Subject with a history of invasive or noninvasive mechanical ventilation within 4 weeks prior to screening; * Subject who has taken prednisone tablets orally at a dose of ≥ 20 mg/day (or equivalent amount of other oral corticosteroids) within 4 weeks prior to screening; * Subject with major lung diseases other than COPD by assessment of investigators at screening; * Subject with severe systemic diseases other than lung within 6 months prior to screening and assessed to be inappropriate to participate in this trial by investigators; * Subject with severe anemia or poorly controlled granulocyte deficiency, thrombocytopenia by assessment of investigators; * Subject with abnormal coagulation and assessed to be negative for the safety of fiberoptic bronchoscopy operations at screening; * Subject requiring long-term anticoagulation therapy of using antiplatelet coagulant therapeutic agents and disable to discontinue their medications 1 week prior to cell collection and cell infusion as assessed by investigators; * Subject with a risk of suicide, a history of mental illness or a history of epilepsy at screening; * Subject with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead ECG test at screening; * Subject participated in other clinical trials with interventions within 3 months prior to screening; * Investigators, co-investigators, research coordinators, employees of research participants or research centers, or their family members; * Any circumstance considered to probably increase the risk of patients or interfere with the clinical trial.